BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

BACKGROUND: Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality rates, including heart failure, multisystem end-organ ...

Evidence of myocardial injury does not necessitate a diagnosis of myocarditis. When a cardiac troponin level is over the 99th percentile of the upper reference limit, 6 there exists a spectrum of ...

From 1970 to 2022, overall age‐adjusted heart disease mortality decreased by 66% from 1970 to 2022 (from 761 to 258 per 100 000). In 1970, 91% of all heart disease deaths were ischemic, declining to ...

BACKGROUND: Evaluation of whether dyspnea has a cardiac cause is essential. Guidelines from 2016 were reported to result in a ...

Using the Global Burden of Disease 2021 data, we analyzed the prevalence and disability‐adjusted life years, examining implications across demographics and geographic regions. In 2021, an estimated 54 ...

Although heart transplantation is the preferred therapy for appropriate patients with advanced heart failure, the presence of concomitant renal or hepatic dysfunction can pose a barrier to isolated ...

Circulation: Arrhythmia and Electrophysiology A specialized journal dedicated to advancing the understanding and management of cardiac arrhythmias and electrophysiology Editor-in-Chief: Paul J. Wang, ...

Cardiovascular disease (CVD) is the predominant cause of death globally, accounting for ≈30% of deaths each year. 1 The prevalence of CVD among adults (aged ≥20 years) in the United States was 48.6% ...

BACKGROUND: Clinical guidelines recommend different revascularization strategies for nonculprit lesions in patients with ST-segment–elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI).

Abstract Recent studies have shown that maternal mortality continues to increase for all racial and ethnic groups in the United States. The recent changes in reproductive legal policies combined with ...

Effective medical therapies for patients with PAD should be prescribed to prevent major adverse cardiovascular events and major adverse limb events for patients with PAD, including antiplatelet ...